Conclusions
zoster
ZOSTER
Coadministration of mRNA-1273 booster vaccine with RZV in adults aged ≥50 years was immunologically noninferior to sequential administration and had a safety and reactogenicity profile consistent with both vaccines administered sequentially.
When coadministered, mRNA-1273 COVID-19 booster vaccine and recombinant zoster vaccine had safety profiles and elicited immune responses consistent with when they were administered sequentially, supporting a way to improve vaccination coverage by coadministration and thereby reducing morbidity and mortality.